澳大利亚医疗诊断企业Lumos Diagnostics（ASX：LDX）宣布与美国生物科技公司Phase Scientific达成里程碑式合作。双方签署为期六年的独家分销协议，Lumos将获得FebriDx快速诊断产品在美国市场的独家经销权。
该协议总价值最高可达3.17亿美元（约合22.8亿元人民币），包含立即支付的200万美元首付款项。FebriDx作为创新的即时诊断设备，能够通过指尖血样在十分钟内区分细菌性与病毒性呼吸道感染，其技术曾获美国FDA突破性医疗器械认定。
此次战略合作将显著拓展Lumos在美国体外诊断市场的商业版图。根据协议框架，Phase Scientific将负责产品生产供应，而Lumos则主导美国境内的市场推广与渠道建设。双方将共同推进该产品在急诊科、基层医疗等场景的临床应用。
业内人士指出，这项价值数亿美元的合作凸显了快速诊断技术在北美医疗市场的增长潜力。随着协议落地实施，Lumos有望通过分级销售提成机制获得持续收入来源，为其全球商业化布局提供关键助力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.